Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Shares of CRISPR ... Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next-generation CAR-T therapy candidates ...

CRISPR Therapeutics CRSP is expected to report fourth ... development of two next-generation CAR-T therapy candidates — CTX112 (targeting CD19-positive B-cell malignancies) and CTX131 (targeting ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

CRISPR Therapeutics is developing CTX112 for both hematologic malignancies and autoimmune indications, with an emerging best-in-class profile. CRISPR Therapeutics continues to make significant ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

Immuno-Oncology and Autoimmune Disease (AID): CRISPR Therapeutics is developing CTX112 for both hematologic malignancies and autoimmune indications, with an emerging best-in-class profile.